Conference call and webcast scheduled for Tuesday, November 13 at 14:30 CET/8:30 am EST Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ( $170 million ) as

Conference call and webcast scheduled for Tuesday, September 11 th at 2:30 pm CET / 8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pancreatic cancer initiated and open for patient enrollment Phase 2 trial in